Cerianna is an FDA approved molecular imaging agent that has the ability to tell the doctor the receptor status of all the tumors—essentially creating a “whole-body" picture of estrogen receptor (ER) positive lesions in recurrent or metastatic breast cancer (MBC). The ability of physicians to more precisely “visualize” the disease may be instructive in determining the most appropriate course of treatment. Cerianna is administered as a single intravenous injection, and then imaged using a Positron Emission Tomography (PET) scan. Cerianna is used as an adjunct to biopsy.
An expert panel of leading healthcare oncology providers and researchers have recently identified a number of potential clinical use cases for Cerianna including: detecting ER+ lesions when considering endocrine therapy for patients at initial diagnosis with MBC or after progression of metastatic disease; and assessing ER status of lesions that are difficult or dangerous to biopsy, when other imaging tests are uncertain or suspicious. or biopsy is non-diagnostic.
Breast Cancer is Personal. Shouldn’t your Diagnostic Imaging Test Be as Well? Listen to the episode for all the most latest clinical updates on Cerianna and check out our episode notes on our website for more information. Our thanks to GE Healthcare for their support of this podcast.